Skip to main content

Table 2 Blood pressure lowering medication at baseline and end of follow-up

From: Effect of the addition of rosiglitazone to metformin or sulfonylureas versus metformin/sulfonylurea combination therapy on ambulatory blood pressure in people with type 2 diabetes: A randomized controlled trial (the RECORD study)

  Background metformin Background sulfonylurea
  + rosiglitazone + sulfonylurea + rosiglitazone + metformin
Modified ITT population (n) 176 165 160 167
Type of medication (n (%))     
   Baseline     
    Any BP medication 119 (68) 112 (68) 104 (65) 114 (68)
    ACEi/ARB 91 (52) 83 (50) 80 (50) 88 (53)
    β-blocker 44 (25) 42 (25) 34 (21) 43 (26)
    CCB 37 (21) 33 (20) 28 (17) 36 (22)
    Diuretics 28 (16) 34 (21) 26 (16) 38 (23)
   End of follow-up*     
    Any BP medication 131 (74) 124 (75) 119 (74) 121 (72)
    ACEi/ARB 99 (56) 93 (56) 89 (56) 92 (55)
    β-blocker 51 (29) 53 (32) 40 (25) 46 (27)
    CCB 47 (27) 39 (24) 32 (20) 40 (24)
    Diuretics 48 (27) 39 (24) 34 (21) 41 (25)
Number of drug classes (n (%))     
   Baseline     
    0 57 (32) 53 (32) 56 (35) 53 (32)
    1 62 (35) 47 (28) 51 (32) 47 (28)
    2 34 (19) 45 (27) 37 (23) 43 (26)
    3 17 (10) 15 (9) 14 (9) 20 (12)
    > 3 6 (3) 5 (3) 2 (1) 4 (2)
   End of follow-up     
    0 45 (25) 41 (25) 41 (26) 46 (27)
    1 57 (32) 47 (28) 58 (36) 45 (27)
    2 34 (19) 47 (28) 41 (26) 50 (30)
    3 27 (15) 22 (13) 15 (9) 19 (11)
    > 3 13 (7) 8 (5) 5 (3) 7 (4)
  1. Data are n or n (%).
  2. ACEi, ACE inhibitor; ARB, angiotensin receptor blocker; CCB, calcium channel blocker.
  3. *End of follow-up refers to time of stopping dual combination therapy or 12 months, whichever is sooner